Modeling the effects of treating diabetic wounds with engineered skin substitutes

In this paper, a novel mathematical model of wound healing in both normal and diabetic cases is presented, focusing upon the effects of adding two currently available commercial engineered skin substitute therapies to the wound (Apligraf™ and Dermagraft™). Our work extends a previously developed model, which considers inflammatory and repair macrophage dynamics in normal and diabetic wound healing. Here, we extend the model to include equations for platelet‐derived growth factor concentration, fibroblast density, collagen density, and hyaluronan concentration. This enables us to examine the variation of these components in both normal and diabetic wound healing cases, and to model the treatment protocols of these therapies. Within the context of our model, we find that the key component to successful healing in diabetic wounds is hyaluronan and that the therapies work by increasing the amount of hyaluronan available in the wound environment. The time‐to‐healing results correlate with those observed in clinical trials and the model goes some way to establishing an understanding of why diabetic wounds do not heal, and how these treatments affect the diabetic wound environment to promote wound closure.

[1]  M. Sporn,et al.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Edward,et al.  Tumour regulation of fibroblast hyaluronan expression: a mechanism to facilitate tumour growth and invasion. , 2005, Carcinogenesis.

[3]  T. D. Mast,et al.  Simulation of ultrasonic pulse propagation through the abdominal wall. , 1997, The Journal of the Acoustical Society of America.

[4]  D. Deheer,et al.  Hyalgan® has a dose‐dependent differential effect on macrophage proliferation and cell death , 2003, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[5]  D. Margolis,et al.  Clinical Protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF‐B for the treatment of a diabetic insensate foot ulcer , 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[6]  B H Perry,et al.  Efficacy and safety of becaplermin (recombinant human platelet‐derived growth factor‐BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[7]  M. Límová.  New therapeutic options for chronic wounds. , 2002, Dermatologic clinics.

[8]  G. Abatangelo,et al.  Healing of hyaluronic acid-enriched wounds: histological observations. , 1983, The Journal of surgical research.

[9]  Gary R. Grotendorst,et al.  Stimulation of granulation tissue formation by platelet-derived growth factor in normal and diabetic rats. , 1985, The Journal of clinical investigation.

[10]  B. Bhandari,et al.  Platelet-derived growth factor (PDGF) BB homodimer regulates PDGF A- and PDGF B-chain gene transcription in human mesangial cells. , 1994, The Biochemical journal.

[11]  H. V. Waugh,et al.  Macrophage Dynamics in Diabetic Wound Dealing , 2006, Bulletin of mathematical biology.

[12]  W. Marston,et al.  Dermagraft®, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer , 2004, Expert review of medical devices.

[13]  J. R. Mekkes,et al.  Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation , 1999, Archives of Dermatological Research.

[14]  J A Sherratt,et al.  Mathematical modelling of nitric oxide activity in wound healing can explain keloid and hypertrophic scarring. , 2000, Journal of theoretical biology.

[15]  A. Hansson,et al.  Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of L‐lactate , 1998, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[16]  E. Middelkoop,et al.  Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. , 1998, The Journal of investigative dermatology.

[17]  I. Darby,et al.  Apoptosis is increased in a model of diabetes-impaired wound healing in genetically diabetic mice. , 1997, International Journal of Biochemistry and Cell Biology.

[18]  D. Greenhalgh,et al.  Cutaneous Wound Healing , 2007, Journal of burn care & research : official publication of the American Burn Association.

[19]  G. Sibbald,et al.  Recombinant human platelet‐derived growth factor‐BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open‐label clinical evaluation of efficacy , 2000, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[20]  K. H. Lee,et al.  Tissue-engineered human living skin substitutes: development and clinical application. , 2000, Yonsei medical journal.

[21]  H. Ockenfels,et al.  Growth factors and interactive dressings in wound repair , 2002 .

[22]  Richard A.F. Clark,et al.  The Molecular and Cellular Biology of Wound Repair , 2012, Springer US.

[23]  M. Streit,et al.  Apligraf – a Living Human Skin Equivalent for the Treatment of Chronic Wounds , 2000, The International journal of artificial organs.

[24]  A. Brody,et al.  Interferon-gamma modulates lung macrophage production of PDGF-BB and fibroblast growth. , 1996, Journal of lipid mediators and cell signalling.

[25]  H. Moses,et al.  Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. , 1987, The Journal of clinical investigation.

[26]  G. Naughton,et al.  Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers , 1999, Diabetes, obesity & metabolism.

[27]  A. Brody,et al.  Interferon-γ modulates lung macrophage production of PDGF-BB and fibroblast growth , 1996 .

[28]  C. Haslett,et al.  In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. , 1996, Journal of immunology.

[29]  W. Marston,et al.  The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. , 2003, Diabetes care.

[30]  M. Embleton.  The Macrophage (2nd Edn) , 2003, British Journal of Cancer.

[31]  G. Naughton,et al.  A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. , 2008, Artificial organs.

[32]  J. Massagué,et al.  Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. , 1986, The Journal of biological chemistry.

[33]  J. Mansbridge,et al.  Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range. , 1998, Tissue engineering.

[34]  D. Steed,et al.  Wound healing: biologic features and approaches to maximize healing trajectories. , 2001, Current problems in surgery.

[35]  G. Naughton,et al.  From Lab Bench to Market , 2002 .

[36]  F. Facchiano,et al.  The chemotactic and mitogenic effects of platelet-derived growth factor-BB on rat aorta smooth muscle cells are inhibited by basic fibroblast growth factor. , 2000, Journal of cell science.

[37]  J. Hanft,et al.  The Efficacy and Safety of Dermagraft in Improving the Healing of Chronic Diabetic Foot Ulcers , 2003 .

[38]  G. Plosker,et al.  Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers. , 2002, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[39]  Min Huang,et al.  IL-7 inhibits fibroblast TGF-β production and signaling in pulmonary fibrosis , 2002 .

[40]  G. Naughton,et al.  From lab bench to market: critical issues in tissue engineering. , 2002, Annals of the New York Academy of Sciences.

[41]  E. Baker,et al.  Growth factor profiles in intraperitoneal drainage fluid following colorectal surgery: Relationship to wound healing and surgery , 2003, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[42]  T. Jenssen,et al.  Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. , 2000, Diabetes.

[43]  Z. Cohn,et al.  The macrophage. , 1973, International review of cytology.

[44]  Vincent Falanga,et al.  The chronic wound: impaired healing and solutions in the context of wound bed preparation. , 2004, Blood cells, molecules & diseases.